Recursion Pharmaceuticals Inc. (RXRX)
RXRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1601830/000160183026000039/0001601830-26-000039-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RXRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001601830 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $74.7M |
| Net income | -$644.8M |
| Operating income | -$648.1M |
| Net margin | -863.4% |
| Operating margin | -867.9% |
| Revenue growth | +26.9% |
| Cash | $743.3M |
| Total assets | $1.5B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 24.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-02 |
| Cash and burn | $549.9M cash; operating cash flow -$77.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 622,759,259 (2026-10-26). | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-10-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Seattle, Washington, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $8.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $18.6M | -$119.0M | -$77.4M | $549.9M | $11.9M | $68.2M | 10-Q 2026-11-02 |
| Q2 2026 2026-06-30 | $7.7M | -$131.0M | -$105.9M | $545.7M | $14.2M | $54.9M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $6.5M | -$117.5M | -$81.1M | $654.5M | $16.4M | $66.4M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $35.5M | -$108.1M | -$46.1M | $743.3M | $18.7M | $74.7M | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $5.2M | -$162.3M | -$117.4M | $659.8M | $20.8M | $43.7M | 10-Q 2026-11-02 |
| Q2 2025 2025-06-30 | $19.2M | -$171.9M | -$76.4M | $525.1M | $22.9M | $64.6M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $14.7M | -$202.5M | -$132.0M | $500.5M | $25.0M | $59.8M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $4.5M | -$178.9M | -$115.4M | $594.4M | $27.4M | $58.8M | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-15 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-02 |
| Latest current report | 8-K | 2026-11-02 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 993 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.5% |
| 1 month | -16.9% |
| 3 months | -3.8% |
| Year to date | -22.1% |
| 1 year | -26.4% |
| From 52-week high | -35.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| COAG | Hemab Therapeutics Holdings Inc. | $39.05 | -4.42% | $1.8B |
| MAZE | Maze Therapeutics Inc. | $33.90 | -1.25% | $1.9B |
| WWB | Windward Bio Group AG Common Shares | $30.04 | +5.40% | $1.7B |
| ALVO | Alvotech | $4.41 | +5.13% | $1.7B |
| BCRX | BioCryst Pharmaceuticals Inc. | $7.45 | -2.10% | $1.9B |
| VIR | Vir Biotechnology Inc. | $9.58 | -3.82% | $1.6B |
| MESO | Mesoblast Limited | $12.45 | -6.18% | $1.6B |
| REPL | Replimune Group Inc. | $21.41 | -2.19% | $2.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier